Three Seasons Wealth LLC Buys New Holdings in Zoetis Inc. (NYSE:ZTS)

by · The Markets Daily

Three Seasons Wealth LLC acquired a new position in shares of Zoetis Inc. (NYSE:ZTS – Free Report) in the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor acquired 7,177 shares of the company’s stock, valued at approximately $1,169,000.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Norges Bank acquired a new position in Zoetis in the fourth quarter valued at $824,321,000. Wellington Management Group LLP lifted its position in shares of Zoetis by 78.5% during the 4th quarter. Wellington Management Group LLP now owns 6,958,543 shares of the company’s stock valued at $1,133,755,000 after acquiring an additional 3,059,255 shares during the period. Raymond James Financial Inc. purchased a new stake in Zoetis during the fourth quarter worth $196,651,000. Polen Capital Management LLC grew its stake in Zoetis by 17.5% in the 4th quarter. Polen Capital Management LLC now owns 7,483,194 shares of the company’s stock valued at $1,219,237,000 after acquiring an additional 1,116,541 shares during the last quarter. Finally, Capital Research Global Investors acquired a new position in shares of Zoetis during the 4th quarter worth approximately $178,688,000. Institutional investors and hedge funds own 92.80% of the company’s stock.

Zoetis Stock Up 1.1 %

Shares of Zoetis stock opened at $152.52 on Friday. The business’s fifty day moving average price is $158.96 and its two-hundred day moving average price is $168.86. The company has a market capitalization of $68.05 billion, a P/E ratio of 27.88, a PEG ratio of 2.78 and a beta of 0.92. Zoetis Inc. has a 1-year low of $139.70 and a 1-year high of $200.33. The company has a debt-to-equity ratio of 1.09, a current ratio of 1.75 and a quick ratio of 1.08.

Zoetis (NYSE:ZTS – Get Free Report) last issued its quarterly earnings results on Thursday, February 13th. The company reported $1.40 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.37 by $0.03. Zoetis had a return on equity of 53.82% and a net margin of 26.86%. The company had revenue of $2.32 billion for the quarter, compared to analysts’ expectations of $2.30 billion. As a group, research analysts forecast that Zoetis Inc. will post 6.07 EPS for the current year.

Zoetis Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 3rd. Stockholders of record on Monday, April 21st will be given a dividend of $0.50 per share. The ex-dividend date is Monday, April 21st. This represents a $2.00 annualized dividend and a dividend yield of 1.31%. Zoetis’s dividend payout ratio (DPR) is 36.56%.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently weighed in on ZTS shares. Stifel Nicolaus cut their price objective on shares of Zoetis from $180.00 to $165.00 and set a “buy” rating for the company in a research report on Monday, April 14th. Piper Sandler boosted their price objective on shares of Zoetis from $200.00 to $205.00 and gave the stock an “overweight” rating in a research note on Thursday, February 27th. Morgan Stanley reduced their target price on shares of Zoetis from $243.00 to $238.00 and set an “overweight” rating on the stock in a research report on Friday, February 14th. StockNews.com upgraded Zoetis from a “hold” rating to a “buy” rating in a report on Friday, March 7th. Finally, Barclays lifted their price target on Zoetis from $242.00 to $244.00 and gave the stock an “overweight” rating in a research note on Friday, February 14th. One research analyst has rated the stock with a hold rating, ten have given a buy rating and two have issued a strong buy rating to the company. According to MarketBeat.com, Zoetis currently has a consensus rating of “Buy” and a consensus target price of $214.40.

Read Our Latest Stock Analysis on Zoetis

Insider Buying and Selling

In other news, EVP Roxanne Lagano sold 326 shares of the stock in a transaction that occurred on Monday, March 10th. The shares were sold at an average price of $170.00, for a total value of $55,420.00. Following the completion of the sale, the executive vice president now directly owns 15,781 shares of the company’s stock, valued at $2,682,770. This represents a 2.02 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Willie M. Reed sold 1,210 shares of Zoetis stock in a transaction on Tuesday, March 11th. The shares were sold at an average price of $166.14, for a total transaction of $201,029.40. Following the sale, the director now directly owns 11,245 shares of the company’s stock, valued at $1,868,244.30. This trade represents a 9.71 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 1,862 shares of company stock worth $312,254 in the last ninety days. 0.16% of the stock is currently owned by corporate insiders.

Zoetis Profile

(Free Report)

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.

Featured Stories

Want to see what other hedge funds are holding ZTS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zoetis Inc. (NYSE:ZTS – Free Report).